NASDAQ:STIM Neuronetics (STIM) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free STIM Stock Alerts $4.80 +0.04 (+0.84%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$4.55▼$4.9050-Day Range$2.79▼$4.8052-Week Range$1.03▼$4.99Volume140,664 shsAverage Volume254,494 shsMarket Capitalization$142.85 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Neuronetics alerts: Email Address Neuronetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside66.7% Upside$8.00 Price TargetShort InterestHealthy0.18% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 14 Articles This WeekInsider TradingSelling Shares$519,307 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.92) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.01 out of 5 starsMedical Sector395th out of 939 stocksSurgical & Medical Instruments Industry48th out of 99 stocks 3.3 Analyst's Opinion Consensus RatingNeuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Neuronetics has a forecasted upside of 66.7% from its current price of $4.80.Amount of Analyst CoverageNeuronetics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.18% of the outstanding shares of Neuronetics have been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently decreased by 64.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for STIM. Previous Next 3.0 News and Social Media Coverage News SentimentNeuronetics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Neuronetics this week, compared to 1 article on an average week.Search Interest9 people have searched for STIM on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows5 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $519,307.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($0.92) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About Neuronetics Stock (NASDAQ:STIM)Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Read More STIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STIM Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comNeuronetics wins FDA clearance for device to treat adolescents with depressionMarch 27, 2024 | finance.yahoo.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 27, 2024 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | markets.businessinsider.comBuy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD MarketMarch 27, 2024 | americanbankingnews.comNeuronetics (NASDAQ:STIM) Given Market Perform Rating at William BlairMarch 25, 2024 | msn.comNeuronetics’s NeuroStar wins FDA clearance for adolescents with depressionMarch 25, 2024 | finanznachrichten.deNeuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 25, 2024 | marketwatch.comNeuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21March 25, 2024 | markets.businessinsider.comNeuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New IndicationMarch 25, 2024 | globenewswire.comNeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionMarch 16, 2024 | finance.yahoo.comSTIM Apr 2024 5.000 putMarch 12, 2024 | msn.comNeuronetics and Transformations Care Network Join Forces to Expand Availability of Innovative Depression TreatmentMarch 7, 2024 | seekingalpha.comNeuronetics, Inc. (STIM) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comNeuronetics Inc (STIM) Reports Record Revenues in Q4 and Full Year 2023March 7, 2024 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | globenewswire.comNeuronetics Announces 5-Year Exclusive Partnership with Transformations Care NetworkMarch 6, 2024 | msn.comNeuronetics GAAP EPS of -$0.19 beats by $0.07, revenue of $20.31M beats by $0.31MMarch 6, 2024 | finance.yahoo.comNeuronetics Full Year 2023 Earnings: US$1.05 loss per share (vs US$1.38 loss in FY 2022)March 5, 2024 | finance.yahoo.comNeuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating ResultsMarch 5, 2024 | globenewswire.comNeuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating ResultsMarch 4, 2024 | msn.comNeuronetics Q4 2023 Earnings PreviewFebruary 22, 2024 | msn.comNeuronetics Set to Announce Q4 2023 Financial Results, Highlights Advances in Mental Health TreatmentFebruary 20, 2024 | finance.yahoo.comNeuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference CallFebruary 20, 2024 | globenewswire.comNeuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference CallFebruary 14, 2024 | msn.comNeuronetics Revamps TrakStar System, Streamlining Patient Data ManagementSee More Headlines Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:STIM CUSIPN/A CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees203Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+66.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,190,000.00 Net Margins-42.31% Pretax Margin-42.31% Return on Equity-72.76% Return on Assets-29.25% Debt Debt-to-Equity Ratio1.73 Current Ratio4.73 Quick Ratio4.33 Sales & Book Value Annual Sales$71.35 million Price / Sales2.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book4.07Miscellaneous Outstanding Shares29,760,000Free Float28,209,000Market Cap$142.85 million OptionableOptionable Beta2.38 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Keith J. Sullivan (Age 66)President, CEO & Director Comp: $1.53MMr. Stephen J. Furlong M.S. (Age 60)Executive VP, CFO & Treasurer Comp: $787.87kMr. W. Andrew Macan (Age 51)Executive VP, GC, Chief Compliance Officer & Corporate Secretary Comp: $646.55kMr. Rusty PageSenior VP of Operations & QualityMs. Lisa Metzner-RosasSenior VP & Chief Marketing OfficerMs. Sara GrubbsSenior VP & Chief Revenue OfficerMr. Rick GrubbsSenior Vice President of National AccountsMr. Cory S. AndersonSenior Vice President of R&D and ClinicalMore ExecutivesKey CompetitorsTELA BioNASDAQ:TELAHealth Sciences Acquisitions Co. 2NASDAQ:HSAQClearPoint NeuroNASDAQ:CLPTDelcath SystemsNASDAQ:DCTHQuipt Home MedicalNASDAQ:QIPTView All CompetitorsInsiders & InstitutionsWilliam Andrew MacanSold 22,377 sharesTotal: $70,711.32 ($3.16/share)Stephen FurlongSold 21,272 sharesTotal: $70,835.76 ($3.33/share)Keith J SullivanSold 20,292 sharesTotal: $66,963.60 ($3.30/share)Keith J SullivanSold 20,851 sharesTotal: $67,348.73 ($3.23/share)Keith J SullivanSold 23,958 sharesTotal: $70,915.68 ($2.96/share)View All Insider TransactionsView All Institutional Transactions STIM Stock Analysis - Frequently Asked Questions Should I buy or sell Neuronetics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STIM shares. View STIM analyst ratings or view top-rated stocks. What is Neuronetics' stock price target for 2024? 2 brokers have issued 1 year price targets for Neuronetics' shares. Their STIM share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price. View analysts price targets for STIM or view top-rated stocks among Wall Street analysts. How have STIM shares performed in 2024? Neuronetics' stock was trading at $2.90 at the beginning of the year. Since then, STIM stock has increased by 65.5% and is now trading at $4.80. View the best growth stocks for 2024 here. Are investors shorting Neuronetics? Neuronetics saw a drop in short interest in March. As of March 15th, there was short interest totaling 53,200 shares, a drop of 64.9% from the February 29th total of 151,700 shares. Based on an average trading volume of 204,300 shares, the short-interest ratio is currently 0.3 days. View Neuronetics' Short Interest. When is Neuronetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our STIM earnings forecast. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.07. The firm had revenue of $20.31 million for the quarter, compared to analysts' expectations of $19.73 million. Neuronetics had a negative net margin of 42.31% and a negative trailing twelve-month return on equity of 72.76%. During the same quarter last year, the firm earned ($0.30) EPS. What guidance has Neuronetics issued on next quarter's earnings? Neuronetics updated its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $16.7 million-$17.7 million, compared to the consensus revenue estimate of $17.0 million. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST). When did Neuronetics IPO? Neuronetics (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. Who are Neuronetics' major shareholders? Neuronetics' stock is owned by many different institutional and retail investors. Top institutional investors include Cannell Capital LLC (9.57%), Balyasny Asset Management L.P. (4.90%), Kent Lake Capital LLC (3.86%), Millrace Asset Group Inc. (2.51%), Thompson Siegel & Walmsley LLC (0.65%) and Dimensional Fund Advisors LP (0.40%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan. View institutional ownership trends. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:STIM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.